{"product_id":"tevapharm-pestle-analysis","title":"Teva Pharmaceutical Industries PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Shortcut to Market Insight Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eTeva faces regulatory scrutiny, pricing pressure, and supply-chain challenges but also benefits from biosimilar opportunities and R\u0026amp;D scale—our PESTLE distills these forces into strategic implications you can act on. Purchase the full PESTLE for a detailed, ready-to-use breakdown that informs investment decisions, competitive strategy, and risk mitigation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical instability in the Middle East\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs an Israeli-headquartered multinational, Teva is exposed to Middle East geopolitical instability that can disrupt supply chains and endanger staff; in 2024 Israel-related operations accounted for roughly 8-10% of Teva’s global workforce and notable R\u0026amp;D centers, heightening risk to continuity.\u003c\/p\u003e\n\u003cp\u003eDespite a global manufacturing footprint—over 30 production sites worldwide—administrative and R\u0026amp;D concentration in Israel makes institutional stability key to investor confidence after Teva’s 2023-24 debt refinancing of about $8–9 billion.\u003c\/p\u003e\n\u003cp\u003ePolitical shifts force robust contingency planning; Teva’s risk mitigation includes multi-sourcing, inventory buffers and alternate routing to protect global drug supplies and reduce potential revenue volatility in affected quarters.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eU.S. Healthcare policy and drug pricing legislation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Inflation Reduction Act’s drug pricing provisions and Medicare negotiation framework, affecting drugs from 2023 onward, are reshaping Teva’s largest market where U.S. sales were $8.9B in 2024; political drive to cut patient out-of-pocket costs tightens reimbursement for both generics and specialty drugs and could pressure margins. Ongoing federal and state transparency mandates on price hikes and PBM rebates increase compliance costs and commercial uncertainty for Teva.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal trade relations and protectionism\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOngoing trade tensions among the U.S., China and EU disrupt API sourcing for Teva, with 2024 import data showing 28% of APIs for its generics came from Asia, raising supply-chain risk and volatility in input costs.\u003c\/p\u003e\n\u003cp\u003ePolitical pushes to near-shore or friend-shore essential medicine production have led Teva to invest in regional capacity, increasing capex by an estimated $250–350m in 2024–25 to reconfigure manufacturing footprints.\u003c\/p\u003e\n\u003cp\u003eTariffs and export controls on chemical precursors—notably China’s 2023 restrictions on several intermediates—can bottleneck high-volume generics production, risking margin compression across Teva’s $7–8bn annual generics revenue base.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare infrastructure investment in emerging markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGovernment stability and rising public health budgets in Latin America and Southeast Asia—health expenditures growing ~4–6% CAGR 2019–2024 in several markets—create scale opportunities for Teva’s generics, aligning with its cost-leadership model as universal coverage commitments boost affordable-medicine demand.\u003c\/p\u003e\n\u003cp\u003ePolitical turnover, however, risks abrupt procurement rule changes and local-preference laws that can cut margins or delay tenders; example: recent procurement shifts in Philippines and Brazil altered generic sourcing in 2023–2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRising public health spend (4–6% CAGR) expands volume for generics\u003c\/li\u003e\n\u003cli\u003eUniversal coverage commitments increase demand for affordable medicines\u003c\/li\u003e\n\u003cli\u003ePolitical turnover can trigger sudden procurement\/local-preference changes (Philippines, Brazil 2023–24)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory harmonization initiatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRegulatory cooperation between FDA and EMA on manufacturing standards and trial-data sharing accelerates Teva’s global approvals, lowering time-to-market for generics and branded products; FDA-EMA pilot programs cut review redundancy by an estimated 10–20% in recent biosimilar dossiers (2023–2024).\u003c\/p\u003e\n\u003cp\u003eAligned biosimilar pathways enable faster launches and cost savings—global development expenses per biosimilar can fall by up to $50–100M when parallel filings replace duplicated trials.\u003c\/p\u003e\n\u003cp\u003ePolitical divergence, however, forces duplicate studies and dossiers, potentially adding 12–24 months and tens of millions in costs for multi-jurisdictional launches.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFDA-EMA cooperation reduces review redundancy ~10–20% (2023–24)\u003c\/li\u003e\n\u003cli\u003eBiosimilar parallel filings can save $50–100M development costs\u003c\/li\u003e\n\u003cli\u003eDivergent standards may add 12–24 months and substantial extra costs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTeva: Geopolitics, U.S. pricing \u0026amp; API risks vs. biosimilar review gains\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTeva faces Middle East geopolitical risk (8–10% workforce\/R\u0026amp;D in Israel, 2024), U.S. pricing pressure (U.S. sales $8.9B in 2024; IRA Medicare negotiation), API supply risk (28% APIs from Asia, 2024) and increased capex for near-shoring ($250–350M projected 2024–25); FDA‑EMA cooperation shortens biosimilar reviews ~10–20% (2023–24), while trade\/tariff shifts and procurement changes in LATAM\/SE Asia create margin volatility.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2023–24\/2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. sales\u003c\/td\u003e\n\u003ctd\u003e$8.9B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIsrael staff\/R\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e8–10%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPIs from Asia\u003c\/td\u003e\n\u003ctd\u003e28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNear‑shore capex\u003c\/td\u003e\n\u003ctd\u003e$250–350M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how macro-environmental forces uniquely affect Teva Pharmaceutical Industries across Political, Economic, Social, Technological, Environmental, and Legal dimensions, with data-driven subpoints and forward-looking insights to identify risks and opportunities for executives, investors, and strategists.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, visually segmented PESTLE summary for Teva Pharmaceutical that highlights key political, economic, social, technological, legal, and environmental risks—ideal for quick reference in meetings or slide decks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal inflationary pressures and manufacturing costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRising raw material, energy and labor costs have compressed Teva’s gross margins, with 2024 Q3 reported gross margin at about 34.5% versus 36.8% year‑earlier, hitting the low‑margin generics where prices are capped by tenders and reimbursement rules; management reported a 6% rise in COGS per unit YTD 2024 and is prioritizing supply‑chain optimization and productivity measures to offset inflationary pressure.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInterest rate environment and debt management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTeva entered 2025 with net debt around $20.5 billion after 2024 asset sales and repayments, leaving it highly sensitive to global rate moves; a 100bps rise in benchmark rates would meaningfully increase annual interest expense given its floating-rate borrowings. High rates raise refinancing costs for maturing debt (next major maturities in 2026–2027), constraining funds for M\u0026amp;A and R\u0026amp;D. Maintaining deleveraging—targeting net debt\/EBITDA below 3x—is watched closely by investors and rating agencies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency exchange rate volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eReporting in U.S. dollars while operating across 60+ currencies exposes Teva to FX risk; in 2024 FX movements drove approximately a $300–500 million swing in reported results, notably from the euro and New Israeli shekel, and depreciation in key emerging-market currencies amplified revenue volatility.\u003c\/p\u003e\n\u003cp\u003eNon-cash translation effects can materially alter quarterly EBITDA and net income; for example, a 5% euro weakening versus the dollar can translate to double‑digit millions in reported revenue declines.\u003c\/p\u003e\n\u003cp\u003eRobust hedging—forward contracts, options, and natural hedges—remains essential to stabilize cash flows and protect margins against unpredictable currency devaluations across Europe, Israel, and emerging markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarket demand for cost-effective generics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEconomic downturns and tighter national health budgets accelerate shifts from costly biologics to generics and biosimilars; global generic drug spending grew to about 430 billion USD in 2024, supporting demand for Teva’s portfolio.\u003c\/p\u003e\n\u003cp\u003eThis counter-cyclical dynamic gives Teva resilience during slowdowns—Teva reported generics revenue of ~8.1 billion USD in 2024, reinforcing its value proposition as payers trim costs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 global generic market ~430 billion USD\u003c\/li\u003e\n\u003cli\u003eTeva 2024 generics revenue ~8.1 billion USD\u003c\/li\u003e\n\u003cli\u003ePayers increasing use of biosimilars to reduce expenditures\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsolidation of the pharmaceutical distribution channel\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe U.S. pharmaceutical distribution is highly consolidated: three wholesalers (McKesson, Cardinal, AmerisourceBergen) and large PBMs control over 70% of drug purchasing, exerting downward price pressure that squeezed manufacturer margins; Teva reported a 2024 U.S. generic price decline contributing to a 6-8% margin compression in recent quarters.\u003c\/p\u003e\n\u003cp\u003eTo retain shelf placement and formulary access, Teva competes on price and relies on volume-based contracts and rebates; strategic negotiations with PBMs and GPOs are essential as single large contracts can represent \u0026gt;10% of U.S. sales for a given molecule.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTop 3 wholesalers \u0026gt;70% buying power\u003c\/li\u003e\n\u003cli\u003e2024 U.S. generic price declines drove ~6-8% margin hit\u003c\/li\u003e\n\u003cli\u003eVolume\/rebate contracts can account for \u0026gt;10% of sales per drug\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTeva margins slide to 34.5% as $20.5B debt and FX, buyer concentration pressure 2025\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHigher input and labor costs cut 2024 Q3 gross margin to ~34.5% (vs 36.8% y\/y); net debt ~$20.5B entering 2025 with refinancing risk in 2026–27; FX swings (~$300–500M impact in 2024) and U.S. buyer concentration (\u0026gt;70% by top 3 wholesalers) compress prices; generics demand resilient—global market ≈$430B and Teva generics revenue ≈$8.1B (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin Q3\u003c\/td\u003e\n\u003ctd\u003e34.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet debt\u003c\/td\u003e\n\u003ctd\u003e$20.5B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFX impact\u003c\/td\u003e\n\u003ctd\u003e$300–500M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal generics\u003c\/td\u003e\n\u003ctd\u003e$430B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTeva generics\u003c\/td\u003e\n\u003ctd\u003e$8.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eTeva Pharmaceutical Industries PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Teva Pharmaceutical Industries PESTLE analysis you’ll receive after purchase—fully formatted and ready to use, with political, economic, social, technological, legal, and environmental factors analyzed.\u003c\/p\u003e\n\u003cp\u003eThe content and structure visible in this preview are the final file you’ll download immediately after payment—no placeholders, no teasers, just the complete, professionally structured report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751558820217,"sku":"tevapharm-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/tevapharm-pestle-analysis.png?v=1772233002","url":"https:\/\/matrixbcg.com\/products\/tevapharm-pestle-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}